Skip to main content
. Author manuscript; available in PMC: 2019 Oct 1.
Published in final edited form as: Melanoma Res. 2018 Oct;28(5):390–397. doi: 10.1097/CMR.0000000000000474

Figure 4. MLN4924 in combination with IFN-alfa but not vemurafenib results in reduced cell proliferation in BRAF mutant melanoma cells as measured by an MTS assay.

Figure 4

A) A375 cells plated at a density of 5000 cells/well in a 96-well plate were treated with various concentrations of MLN4924 for 72 hours. Following incubation, MTS reagent was added to each well and absorbance at 490 nm was measured. The proliferation IC50 was determined to be 408 nM. B) The same procedure was repeated in A375 cells using 1200 nM MLN4924 with or without IFN-alfa (104 U/mL) or vemurafenib (1 μM). C) Proliferation was measured in Mel39 cells using same procedure as in A. The IC50 value of Mel39 for proliferation was determined to be 142 nM. D) The combination treatment was repeated in Mel39 cells using 1200 nM MLN4924 with or without IFN-alfa (104 U/mL) or vemurafenib (1 μM). Data is presented as mean ± S.E.M. *p<0.05, **p<0.005, ***p<0.0005